DXCM Stock Down -15% after 5-Day Loss Streak
DexCom (DXCM) stock hit day 5 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -15% return. The company has lost about $4.4 Bil in value over the last 5 days, with its current market capitalization at about $30 Bil. The stock remains 2.0% below its value at the end of 2024. This compares with year-to-date returns of 7.6% for the S&P 500.
DXCM designs and commercializes continuous glucose monitoring systems, including the next-generation Dexcom G7, for use in the United States and internationally. Is this drop a warning sign or a setup for rebound? Deep dive with Buy or Sell DXCM.
Comparing DXCM Stock Returns With The S&P 500
The following table summarizes the return for DXCM stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | DXCM | S&P 500 |
|---|---|---|
| 1D | -3.8% | 1.5% |
| 5D (Current Streak) | -14.8% | -0.9% |
| 1M (21D) | -8.8% | 0.8% |
| 3M (63D) | -6.6% | 11.3% |
| YTD 2025 | -2.0% | 7.6% |
| 2024 | -37.3% | 23.3% |
| 2023 | 9.6% | 24.2% |
| 2022 | -15.6% | -19.4% |
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact. Take a look at what history tells you about whether past dips like this have been buying opportunities or traps: DXCM Dip Buyer Analysis.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 33 S&P constituents with 3 days or more of consecutive gains and 39 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 23 | 6 |
| 4D | 0 | 18 |
| 5D | 9 | 5 |
| 6D | 1 | 7 |
| 7D or more | 0 | 3 |
| Total >=3 D | 33 | 39 |
Key Financials for DexCom (DXCM)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $3.6 Bil | $4.0 Bil |
| Operating Income | $597.7 Mil | $600.0 Mil |
| Net Income | $541.5 Mil | $576.2 Mil |
Last 2 Fiscal Quarters:
| Metric | 2024 FQ4 | 2025 FQ1 |
|---|---|---|
| Revenues | $1.1 Bil | $1.0 Bil |
| Operating Income | $188.9 Mil | $133.7 Mil |
| Net Income | $151.7 Mil | $105.4 Mil |
The losing streak DXCM stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.